This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
by Kinjel Shah
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $47, denoting a -6.06% move from the preceding trading day.
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
by Ahan Chakraborty
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
by Zacks Equity Research
TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
by Urmimala Biswas
Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk (NVO) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
by Sundeep Ganoria
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NVIDIA's Story Keeps Getting Brighter
by Derek Lewis
Everybody wants their hands on NVIDIA's GPUs, with the AI favorite continuing to ink fresh deals and collaborate with many notable companies. Has the fun just started?
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
by Ahan Chakraborty
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $65.29, moving 2.61% from the previous trading session.
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
by Kinjel Shah
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
Here's How to Play AbbVie Stock as it Reaches Golden Cross
by Kinjel Shah
ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
by Sundeep Ganoria
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Novo Nordisk (NVO) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $71.01, denoting a +1.89% move from the preceding trading day.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
The Zacks Analyst Blog Highlights SAP SE, Novo Nordisk, Thermo Fisher Scientific and FONAR
by Zacks Equity Research
SAP, NVO, TMO and FONR navigate growth and headwinds as analysts spotlight cloud momentum, obesity drugs, and innovation plays.
Top Research Reports for SAP, Novo Nordisk & Thermo Fisher
by Mark Vickery
SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
by Ahan Chakraborty
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
by Zacks Equity Research
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.